Skip to content
Study details
Enrolling now

SLV-154 Treatment Trial

Solve Therapeutics
NCT IDNCT06771219ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

70

Study length

about 2 years

Ages

18+

Locations

9 sites in CA, MO, NJ +3

What this study is about

This trial is testing SLV-154 in people with advanced cancers. The goal is to see if SLV-154 is safe and how it works in the body, as well as whether it has any effect on cancer cells.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take SLV-154

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: MTD and/or RDR

Secondary: Duration of Response (DOR), Immunogenicity, Objective Response Rate (ORR), Overall survival (OS), Progression-free survival (PFS), SLV-154 Pharmacokinetics, Time to Response (TTR), Time to treatment failure (TTF)

Body systems

Oncology